Policy
A renewal of the FDA’s pediatric rare disease voucher program is couched within a massive $1.2 trillion spending bill the House is set to vote on later this week.
FEATURED STORIES
Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo.
Policy initiatives have come fast and furious at the FDA this year. While guidances on rare diseases and vaccines have consumed most of the ink, policy shifts aimed at improving FDA efficiencies and reshoring U.S. manufacturing also got some attention. Here, BioSpace rounds up more than a dozen initiatives relevant to the biopharma industry.
With five CDER leaders in one year and regulatory proposals coming “by fiat,” the FDA is only making it more difficult to bring therapies to patients.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The U.S. Food and Drug Administration granted emergency use authorization to Rutgers’ RUCDR Infinite Biologics for its test that uses saliva.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 13, 2020.
The Stanford serology test provides results in two to three days and Stanford Health Care can test 500 samples per day. Know what more it has to offer.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 9, 2020.
“We are pleased by the FDA’s approval of Braftovi in combination with cetuximab, as we are committed to developing targeted medicines that can help people living with certain mutation-driven cancers,” said Chris Boshoff, chief development officer, Oncology, Pfizer Global Product Development.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
The designation will allow the company to expedite the development and potential regulatory review of sotatercept.
The CDC findings were based on an analysis of 2,572 known juvenile cases of COVID-19 that were part of a batch of 149,760 laboratory-confirmed COVID-19 cases.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.